Galderma to Showcase Latest

Galderma to Showcase Latest Updates From Its Broad, Innovative and Leading Dermatology Portfolio at the 2024 American Academy of Dermatology Annual Meeting 

• Galderma will present two      late-breaking presentations on clinical trials evaluating the long-term      efficacy of the investigational monoclonal antibody nemolizumab in prurigo      nodularis and its durability in atopic dermatitis^1,2

• Five oral posters and 16      e-posters will also be presented from across Galderma’s aesthetic,      therapeutic dermatology and dermatological skincare portfolio, with data      on acne, sensitive skin, aesthetic improvements and prurigo nodularis

• For the first time, Galderma      will sponsor a symposium on the burden of itch in collaboration with the      U.S. National Eczema Association, featuring renowned dermatology experts      along with patient representatives

ZUG, Switzerland -- (BUSINESS WIRE) --

Galderma, the pure-play dermatology category leader, will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) Annual Meeting from March 8-12, 2024, highlighting its broad, innovative and leading dermatology portfolio. Galderma’s extensive presence – including two late-breaking presentations on its first-in-class, investigational monoclonal antibody nemolizumab, five oral poster presentations, 16 e-posters, a symposium, and several ‘Meet the Expert’ and interactive booth sessions – highlights its commitment to listening to consumers, patients and healthcare professionals in order to deliver cutting-edge science and innovation that addresses their varied needs.

“Our vast presence at AAD combines new data, novel educational activities and patient perspectives, demonstrating how we are putting our commitment to addressing the needs of the dermatology community into action. We particularly look forward to presenting the latest updates from clinical trials of nemolizumab, which was recently accepted for filing by regulatory authorities in the U.S. and EU in prurigo nodularis and atopic dermatitis.”

BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D.
GLOBAL HEAD OF R&D
GALDERMA

Data from across the full spectrum of dermatology to be presented
New data on nemolizumab, a first-in-class, investigational monoclonal antibody specifically designed to provide safe and rapid relief from itch, will be shared at AAD in two late-breaking presentations:

• Results up to 52 weeks from      an interim analysis of the OLYMPIA open-label extension study evaluating      the long-term efficacy and safety of nemolizumab in patients with prurigo      nodularis will be presented on Sunday, March 10, at 3:20 PM PST by Dr.      Shawn Kwatra¹

• Results from an analysis of      two pivotal phase III studies (ARCADIA 1 and ARCADIA 2) evaluating the      efficacy and safety of maintenance treatment with nemolizumab at 48 weeks      in patients with moderate to severe atopic dermatitis will be presented on      Sunday, March 10, at 2:50 PM PST by Dr. Jonathan Silverberg²

Additionally, five oral posters will be presented on Friday, March 08, at the Upper Level, Sails Pavilion, Poster Center 1, including:

• Results from the phase III      READY-3 study evaluating the efficacy and safety of RelabotulinumtoxinA,      our investigational novel, ready-to-use liquid neuromodulator, when used      for combination treatment of frown lines (glabellar lines) and crow’s feet      (lateral canthal lines) at 9:50 to 9:55 AM PST, presented by Dr. Joel      Schlessinger³

• Results from the phase IV      LEAP and START studies, showing that trifarotene improves acne and related      sequelae at 9:05 to 9:10 AM PST, and that it is efficacious and suitable      for a broad range of patient types at 8:35 to 8:40 AM PST, both presented      by Dr. Andrew Alexis^4,5

• Survey results on sensitive      skin, including on dermatologists’ perspectives and educational exposures      at 3:50 to 3:55 PM PST, presented by Dr. Sara Abdel Azim, and primary      hyperhidrosis and sensitive skin syndrome at 10:10 to 10:15 AM PST,      presented by Dr. Cleo Whiting^6,7

Delving into patient and expert perspectives on itch
Our sponsored symposium, Perspectives on itch: Sharing experiences and understanding the burden, conducted in collaboration with the National Eczema Association, will bring together leading experts and patient representatives, Dr. Shawn Kwatra, Dr. Jonathan Silverberg, Dr. Matt Zirwas, and from the U.S. National Eczema Association, Wendy Begolka, to explore how dermatology providers can better recognize and address itch, one of the most burdensome and debilitating symptoms associated with diseases such as atopic dermatitis and prurigo nodularis. The event is taking place on Saturday, March 9, in the Pacific Ballroom 21-26, Marriott Marquis San Diego Marina, from 7:00 to 9:00 PM PST.

More details on Galderma’s scientific presentations at AAD can be found here.
^{*All presenters are paid consultants or employees of Galderma.}

About Galderma
Galderma is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market though Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

1. Kwatra, S, et al. Nemolizumab      long-term efficacy and safety up to 52 weeks in the OLYMPIA open-label      extension study in patients with prurigo nodularis: an interim analysis.      Late-breaking abstract presented at AAD 2024.

2. Silverberg, J, et al.      Maintenance of efficacy and safety with nemolizumab at Week 48: results      from two global phase III pivotal studies (ARCADIA 1 and ARCADIA 2) in      patients with moderate-to-severe atopic dermatitis.      Late-breaking abstract presented at AAD 2024.

3. Schlessinger, S, et al.      Efficacy and safety of a novel formulation liquid botulinum toxin,      RelabotulinumtoxinA, when used for combination treatment of glabellar and      lateral canthal lines. Oral poster presented at AAD 2024.

4. Alexis, A, et al. Trifarotene      shown to improve acne and related sequelae. Oral poster presented at AAD      2024.

5. Alexis, A, et al. Phase IV      studies show trifarotene is efficacious and suitable for broad range of      patient types. Oral poster presented at AAD 2024.

6. Azim, SA, et al. Sensitive      skin: a survey of dermatology resident physicians’ perspectives and      educational exposures. Oral poster presented at AAD 2024.

7. Whiting, C, et al. Primary      hyperhidrosis and sensitive skin syndrome: a national pilot survey. Oral      poster presented at AAD 2024.